Here are four things to know:
1. Organogenesis will become a wholly owned subsidiary of Avista.
2. Avista Capital Partners’ affiliates agreed to invest $92 million in the combined company in conjunction with the transaction.
3. The combined company’s anticipated initial enterprise value is approximately $673 million.
4. Organogenesis offers bioactive and acellular biomaterials products in advanced wound care, sports medicine and surgical biologics, including orthopedics and spine.
More articles on biologics:
6 things to know about Isto Biologics
Biologics may reduce work & activity impairment in axial spondyloarthritis patients, study shows: 4 things to know
Vericel appoints CMO: 3 details
